Attention has focused on patients with coronavirus disease 2019 (COVID-19), frontline responders, and attributable deaths, leading to enlarged intensive care unit and ventilator capacities and reduction of elective care. Subsequently, marginalized populations are easily overlooked, such as patients with severe mental illness who are at high risk for medical comorbidities predisposing them to COVID-19 and whose psychiatric condition can worsen owing to COVID-19 infection.
Severe mental disorders, including schizophrenia, bipolar disorder, and major depressive disorder, are chronic conditions that frequently need maintenance treatment to prevent relapse and rehospitalization. However, in the COVID-19 pandemic, many medical procedures have been reduced, leading to the global challenge of balancing provision of medical resources. For example, the serious disruption of normal medical care has reduced functioning of stroke centers across China because of fear of in-hospital cross-infection and lack of experienced stroke care experts.1
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Kai G. Kahl, MD, Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Carl-Neuberg-Str 1, 30625 Hannover, Germany (firstname.lastname@example.org).
Published Online: June 24, 2020. doi:10.1001/jamapsychiatry.2020.1701
Conflict of Interest Disclosures: Dr Kahl has been a consultant and/or advisor to or has received honoraria from Eli Lilly, Janssen/J&J, Lundbeck, Neuraxpharm, Otsuka, Pfizer, Servier, Schwabe, Takeda and Trommsdorff/Ferrer. He has provided expert testimony for Neuraxpharm, Servier, and Takeda. Dr Correll has been a consultant and/or advisor to or has received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He received grant support from the Berlin Institute of Health, Janssen, the National Institute of Mental Health, Patient-Centered Outcomes Research Institute, Takeda, and the Thrasher Foundation. He received royalties from UpToDate and is also a stock option holder of LB Pharma.
You currently have no searches saved.
You currently have no courses saved.